Featured Articles

31. Optimized And Scalable LNP Composition For RNA Vaccine Delivery 12/20/2023

    Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.

32. Trends In Next-Generation Delivery Technologies 11/22/2023

    Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.

33. Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy 11/22/2023

    Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.

34. How To Improve Lentivirus Polishing Recovery 10/25/2023

    Explore how we used capture with weak anion exchange and optimized the Capto™ Core 700 chromatography resin polishing step to maximize infectious recovery.

35. How To Develop A Scalable AAV Process, From Start To Finish 10/24/2023

    Get highlights from a developed process that has been – and continues to be refined – by Cytiva scientists. These insights are framed around common challenges in AAV development and production.

36. Recommendations For Successful IND Approval Of RNA-LNP Drugs 8/22/2023

    The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.

37. Lowering The Lipid Barrier To RNA-LNP Therapeutics 8/22/2023

    Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.

38. Fast Track RNA-LNP Drug Development By Lowering The Lipid Barrier 8/21/2023

    Fast-track RNA-LNP development, streamline screening with off-the-shelf ionizable lipid mixes, and utilize validation strategies to generate reproducible and scalable LNPs for lead candidates.

39. COGs Process Economics For Autologous Cell Therapy 8/11/2023

    Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and additional insights. Discover how cell therapy manufacturers can combat these costs.

40. Addressing Key TIL Therapy Manufacturing Workflow Challenges 8/11/2023

    From tumor resection to therapy delivery, there are a number of hurdles at each stage of your TIL therapy manufacturing workflow. Here, we address key challenges at each stage of the workflow.